SCHEMBL4887020

SCHEMBL4887020

c1ccc2c(c1)ccc[n+]2CCCCCCCCCCC[n+]1cccc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
BCHE P06276 14/20 1.00
ACHE P22303 14/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14951076 1.00 BCHE (1.00) BCHEACHE
SCHEMBL3606932 1.00 BCHE (1.00) BCHEACHE
SCHEMBL3604422 1.00 BCHE (1.00) BCHEACHE
SCHEMBL3603725 1.00 BCHE (1.00) BCHEACHE
SCHEMBL3588425 1.00 BCHE (1.00) BCHEACHE
SCHEMBL3596114 1.00 BCHE (1.00) BCHEACHE
Bromide SCHEMBL3597256 0.98 BCHE (1.00) BCHEACHE
Bromide SCHEMBL4891809 0.98 BCHE (1.00) BCHEACHE
Iodide SCHEMBL2332855 0.98 BCHE (0.96) BCHEACHE
Bromide SCHEMBL18154058 0.98 BCHE (1.00) BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287490-A1 Bis-pyridino containing compounds for the use in the treatment of CNS pathologies UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2008-11-20 US claimed
US-20050261334-A1 Bis-pyridino containing compounds for the use in the treatment of CNS pathologies UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2005-11-24 US claimed
US-20080287490-A1 Bis-pyridino containing compounds for the use in the treatment of CNS pathologies UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2008-11-20 US disclosed
US-20050261334-A1 Bis-pyridino containing compounds for the use in the treatment of CNS pathologies UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261334-A1 Bis-pyridino containing compounds for the use in the treatment of CNS pathologies SLC18A3, SLC18A2, CHRNB2 BCHE 58/4885ACHE 43/4885
US-20080287490-A1 Bis-pyridino containing compounds for the use in the treatment of CNS pathologies SLC18A3, SLC18A2, CHRNB2 BCHE 58/4885ACHE 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.